Content Type: Article

  • New Year Rings in Material Changes to Medicare Overpayment Rule

    New Year Rings in Material Changes to Medicare Overpayment Rule

    ARTICLE / CLIENT ALERT

    New Year Rings in Material Changes to Medicare Overpayment Rule

    December 19, 2024

    Read time: 14 min

    Key takeaways
    Overview

    The Centers for Medicare and Medicaid Services (CMS) finalized material changes to the overpayment rules for Medicare Parts A, B, C, and D effective January 1, 2025. These changes create new ambiguity and practical challenges for organizations dealing with a potential overpayment. Organizations should consider reviewing their procedures for identifying and returning overpayments to comply with new timelines contained in the regulation. Organizations may also want to consider bringing a legal challenge to aspects of the rule that purport to create obligations that are contrary to the overpayment statute.

    CMS finalized the overpayment final rule as part of the CY 2025 Medicare Physician Fee Schedule final rule that was published in the Federal Register on December 9, 2024 (2025 Rule).

    In depth

    The Overpayment Statute

    Under the Affordable Care Act, “persons” such as providers, suppliers, Medicare Advantage plans, and Part D sponsors that receive an overpayment are required to report and return the overpayment, accompanied by a written notification of the reason for the overpayment.[1] An “overpayment” is defined as “any funds” received or retained under the Medicare or Medicaid programs “to which the person, after applicable reconciliation, is not entitled.”[2] The statutory deadline by which overpayments must be reported and returned is the later of either:

    • 60 days after the overpayment is “identified” or
    • The date any corresponding cost report is due, if any.[3]

    The overpayment statute incorporates the federal False Claims Act (FCA) by reference, providing that retention of an overpayment after the deadline is an “obligation” under the FCA.[4] The FCA contains a “reverse false claims” cause of action for either:

    • Making, using, or causing to be made or used, a false record or statement material to an obligation to pay or transmit money or property to the government or
    • Knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the government.[5]

    Prior Overpayment Rules

    In 2016, CMS issued a final rule with respect to Medicare Part A and Part B (2016 Rule)[6] that defined “identified” as when the person “has, or should have through the exercise of reasonable diligence, determined that [it] has received an overpayment and quantified the amount of the overpayment”[7] (emphasis added). The 2016 Rule preamble discussed “reasonable diligence” as including “proactive compliance activities” and “reactive investigative activities undertaken in response to receiving credible information about a potential overpayment.”[8] CMS discussed a six-month “benchmark” for conducting reactive investigative activities into credible information of a potential overpayment, which could be extended in circumstances where the matter is unusually complex, such as Physician Self-Referral Law issues, or in other extraordinary circumstances, such as natural disasters.

    As a practical matter, many “credible information” investigations can require considerable time given the complexity of Medicare and Medicaid rules and the effort necessary to develop facts, obtain claims data, and engage experts to conduct the review. Many organizations relied on this preamble guidance in conducting these investigations. Once the investigation confirmed the existence and quantified the amount of the overpayment, then the 60-day period to report and return the overpayment began to run.

    2025 Overpayment Rule Changes

    In the preamble to the 2025 Rule, CMS states that the updated rule “provide[s] for consistency in Medicare regulation related to reporting and returning overpayments” in response to a federal district court decision concerning the Medicare Part C overpayment rule. The district court held that the “reasonable diligence” standard impermissibly established FCA liability for mere negligence.[9] CMS proposed changes to the overpayment rules in two iterations. First, a 2022 proposed rule articulated the new “identified” definition finalized in the 2025 Rule.[10] Second, the proposed CY 2025 Physician Fee Schedule rule included additional changes in response to comments on the 2022 proposal. These changes were finalized and included the creation of a new “deadline suspension” provision, discussed below.[11]

    Replacing the “Reasonable Diligence” Standard With “Knowingly”

    The 2025 Rule replaces the “reasonable diligence” standard for identifying an overpayment with the FCA’s “knowingly” standard. Under the 2025 Rule, “a person has identified an overpayment when the person knowingly receives or retains an overpayment. The term ‘knowingly’ has the meaning set forth in 31 U.S.C. § 3729(b)(1)(A).”[12] This change applies to Medicare Parts A, B, C, and D.[13]

    The FCA defines “knowingly” as a person who, with respect to information:

    • Has actual knowledge of the information
    • Acts in deliberate ignorance of the truth or falsity of the information or
    • Acts in reckless disregard of the truth or falsity of the information.[14]

    Under the 2025 Rule, once a person has identified an overpayment, such person then has 60 days to return the overpayment unless one of the deadline suspension reasons applies.[15] CMS states that “in cases where a provider or supplier acts in deliberate ignorance or reckless disregard of the existence of the overpayment, the 60-day period begins on the date that the provider or supplier acted in deliberate ignorance or reckless disregard of the truth or falsity of information regarding the overpayment.”[16]

    Analysis and Implications

    With this change, CMS reverts to the “identified” definition it originally proposed in 2012[17] but changed in the 2014 and 2016 Rules. CMS made those changes based on many industry comments that using the FCA “knowingly” standard to define “identified” was not clearly authorized by the statute, was confusing and ambiguous, and did not provide clear guidance. Those concerns remain. CMS punts on addressing those concerns and requests for greater clarity and tells organizations to look to “FCA caselaw” for the meaning of reckless disregard and deliberate ignorance.

    On the positive side, the revised definition addresses the UnitedHealthcare court’s concerns that the “should have known by exercising reasonable diligence” standard could result in creating FCA reverse false claims liability for simple negligence. CMS also clearly states in the preamble that with respect to an organization that “is actively investigating a potential overpayment, the 60-day period for reporting and returning the overpayment begins when the provider or supplier has actual knowledge of the overpayment.”[18] This statement shows that CMS understands that an organization that is conducting an active investigation into a potential overpayment is by definition not acting recklessly or with deliberate ignorance. CMS also does not articulate a timeline for this initial investigation to occur. These two points should be helpful in ensuring that organizations have adequate time to conduct this initial investigation, but they also highlight the problems with the new “deadline suspension for related overpayments” provision discussed below.

    What qualifies as an “active investigation” is likely an area that regulators and whistleblowers will examine in the future, so organizations should continue to reasonably and timely conduct investigations into potential overpayments. This fact-specific inquiry will include the complexity of the allegations, organizational resources, and unexpected delays in obtaining data. Organizations with “inactive” investigations, or that do not conduct an investigation at all, risk being accused of recklessness or deliberate ignorance.

    CMS provides additional color on its views of recklessness and deliberate ignorance in its response to stakeholder comments. As they did in 2012, commenters pointed out that the overpayment statute includes a definition of “knowingly” but does not actually use the term in the substantive statutory text. CMS states:

    [w]e acknowledge that commenters have stated that the [knowingly] defined terms are not used in the statute, but we see nothing in the statute indicating that this provision is mere surplusage or that Congress intended to create a lower knowledge standard than otherwise exists under the False Claims Act. Such an interpretation would effectively allow [organizations] to “bury their heads in the sand” and deliberately ignore or recklessly disregard overpayments.[19]

    This framing of what qualifies as recklessness or deliberate ignorance may prove useful in combatting allegations that an organization has “identified” an overpayment, especially if the allegation is based on an assertion that the organization is not conducting an investigation fast enough. It should be difficult to characterize an organization that is reviewing a potential overpayment as “burying its head in the sand.”

    Removing Quantification

    The 2025 Rule removes quantification from the definition of “identified” in the Medicare Parts A and B rule. CMS states that “with respect to quantification of the overpayment, once a person has identified an overpayment, as the term is defined at § 401.305(a)(2), the person has 60 days to report and return the overpayment under § 401.305(b)(1)(i), even if the person has not yet calculated the precise amount of the overpayment at the time of identification. Because a person cannot return an indefinite sum, as a practical matter the overpayment amount must be calculated within 60 days of identification to meet the 60-day deadline.”[20]

    Analysis and Implications

    Removing quantification from the “identified” definition is a material change to the overpayment rule that imposes new difficulties, burdens, and risks that impact how organizations approach their overpayment investigations. Practically speaking, this change means that organizations will have to quantify identified overpayments much faster than they have in the past because quantification now occurs during the 60-day returning and reporting period.

    New “Deadline Suspension” for Investigating Related Overpayments

    The 2025 Rule also adds a new provision in the Medicare Parts A and B rule under which the 60-day timeline may be suspended in certain circumstances. The existing rule[21] suspends the 60-day report and return clock in the following instances:

    • Either the US Department of Health and Human Services Office of Inspector General (OIG) or CMS acknowledges receipt of a disclosure under the agencies’ respective disclosure protocols. The clock will remain suspended until a settlement agreement is entered, the person withdraws from the protocol, or the person is removed from the protocol.
    • A person requests an extended repayment schedule as defined in 401.603. The clock will remain suspended until CMS or one of its contractors rejects the extended repayment schedule request or the provider or supplier fails to comply with the terms of the extended repayment schedule.

    Under a new provision at 42 C.F.R. § 401.305(b)(3), the 2025 Rule provides that the 60-day deadline for reporting and returning overpayments will be suspended when both of the following occur:

    • A person has identified an overpayment but has not yet completed a good-faith investigation to determine the existence of related overpayments that may arise from the same or similar cause or reason as the initially identified overpayment and
    • The person conducts a timely, good-faith investigation to determine whether related overpayments exist.[22]

    If the conditions of § 401.305(b)(3)(i) are satisfied, the deadline for reporting and returning the initially identified overpayment and related overpayments that arise from the same or similar cause or reason as the initially identified overpayment will remain suspended until the earlier of:

    • The date that the investigation of related overpayments has concluded and the aggregate amount of the initially identified overpayments and related overpayments is calculated or
    • The date that is 180 days after the date on which the initial identified overpayment was identified.

    Accordingly, if an organization identifies an initial overpayment and “believes” that there may be “related overpayments that arise from the same or similar cause or reason,” the 60-day deadline to return the initial and as-yet-unknown related overpayments is suspended while the organization conducts a good faith investigation into the potential related overpayments for up to 180 days. CMS states that it believes this tolling provision of the 2025 Rule “provides sufficient time [for] providers and suppliers to comply with [the reporting and returning of overpayments] requirements before being exposed to False Claims Act liability.”[23]

    CMS states that this provision “does not impose an independent obligation to investigate related overpayments when a person has actual knowledge of an overpayment.”[24] However, CMS explains its new rule as follows:

    [i]f a person believes related overpayments may exist, § 401.305(b)(3) permits the person up to 180 days to conduct an investigation into the existence of related overpayments, provided that the person conducts a timely, good-faith investigation. Without this provision, persons conducting such investigations might face a rolling series of relatively short-term deadlines as the investigation advances and uncovers additional overpayments, each with its own 60-day deadline.[25]

    Analysis and Implications

    It appears that CMS attempted to address commenters’ request to maintain the six-month benchmark for conducting investigations of potential overpayments in the revised rule. However, CMS finalizing its proposed “related overpayment” suspension provision does the opposite – it purports to create a strict 180-day deadline for conducting an investigation into “related” but not “identified” overpayments following the conclusion of an investigation identifying the “initial” overpayment.

    This provision is clearly inconsistent with the “knowingly” identification definition that CMS adopts in the 2025 Rule. Specifically, CMS ignores the meaning of recklessness and deliberate ignorance by effectively deeming an organization as reckless or deliberately ignorant if its “timely, good faith review” into related overpayments takes longer than 180 days. This “deeming” rule is not supported by the overpayment statute or the FCA caselaw to which CMS directs organizations for an understanding of the meaning of recklessness or deliberate ignorance. If identification includes recklessness and deliberate ignorance, then an organization conducting an active investigation of either the initial or related overpayment is not acting recklessly or with deliberate ignorance. In addition, the FCA reverse false claims cause of action requires that the organization “knowingly conceals or knowingly and improperly avoids or decreases an obligation” (with obligation including returning an overpayment). An organization that is engaged in a reasonable, good faith investigation should not be viewed as knowingly concealing or knowingly or improperly avoiding an obligation.

    Accordingly, this change in the 2025 Rule may be ripe for challenges arguing that CMS exceeded its statutory authority in making such a change, and that its interpretation of the overpayment statute is not the best one, especially in light of the Supreme Court of the United States’ recent decision in Loper Bright Enterprises v. Raimondo.[26]

    Practical Considerations

    Until someone successfully challenges the rule or the next administration amends it, organizations are faced with managing compliance and mitigating risk.

    Investigating Overpayments

    Removing quantification from the identification definition is a major change that will require accelerated quantification efforts once the overpayment has been confirmed. As a result, providers will need to evaluate their current overpayment policies and procedures to identify ways in which such processes may be made more efficient. They may also need to evaluate how to handle an investigation that may be partially, but not completely, concluded at the time the applicable regulatory deadline expires.

    It is also important to remember that the overpayment statute and the 2025 Rule are not the only laws to consider when investigating overpayments. For example, overpayments can create FCA risk in their own right as potential false claims, so identifying and disclosing overpayments helps mitigate FCA risk. Despite the material changes to the overpayment rule implemented by the 2025 Rule, it is important that organizations not lose the forest for the trees. Compliance with the overpayment statute and rule is one component of a larger risk analysis that must be conducted when investigating claims that may be subject to the reporting and returning requirements for overpayments.

    Returning and Reporting Identified Overpayments

    The 2025 Rule also presents a practical question: What should an organization do when it is running up against the 180 days, but the “related” overpayment investigation is not complete (despite good faith efforts) and a final overpayment has not been quantified? There are several approaches that providers might consider in this situation, although like the determination of whether an overpayment has been identified in the first instance, a fact-specific analysis will be required in each case.

    One option for an organization to consider is notifying its Medicare Administrative Contractor, prior to the 180-day period expiring, about the investigation and the nature of the overpayments, and returning the portion of the overpayment that the organization has been able to quantify to date. Another avenue for self-disclosure is through the OIG’s Self-Disclosure Protocol (SDP) or the CMS Self-Referral Disclosure Protocol (SRDP). The overpayment regulations contain a suspension of the 60-day deadline for the return of overpayments from the time OIG or CMS acknowledges receipt of the submission until the time a settlement is reached or the person withdraws or is removed from the SDP or SRDP.[27] However, deciding whether to pursue any of these options will require a careful analysis of the factual situation, including the nature of the overpayment issue and the status of the investigation, and organizations should work with experienced healthcare counsel when making this assessment.

    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Monica Wallace

    Partner

    Chicago

    Dexter Golinghorst

    Associate

    Chicago

    More insights

  • AI and the Law: Emerging Trends in Enforcement

    AI and the Law: Emerging Trends in Enforcement

    ARTICLE / CLIENT ALERT / US POLICY

    AI and the Law: Emerging Trends in Enforcement

    December 19, 2024

    Read time: 10 min

    Key takeaways
    Overview

    Deemed the Fourth Industrial Revolution, artificial intelligence (AI) has emerged as the newest watershed technological development of the 21st century, as evidenced by its near ubiquity in discussions of everything from how the information economy functions to the way art is made. The rapid development and deployment of AI technologies took society and governments by surprise.

    The US government has since taken a variety of wide-ranging aspirational steps, but legislative activity has been absent. Recent actions by federal and state regulators offer insights into the priorities surrounding AI enforcement. Although these priorities, as well as the nature and scale of enforcement, may shift under the new Trump administration, recent enforcement actions demonstrate the tools available for AI enforcement.

    In depth

    In the wake of the explosive emergence of ChatGPT, the Biden administration took a number of executive actions addressing AI but largely focused on policies and positions related to responsible AI use. In October 2023, President Biden issued an executive order for the “Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence,” which underscored the administration’s commitment to the research, development, and deployment of responsible uses of AI. The executive order instructed the US Department of Commerce to develop guidance for content authentication and watermarking to clearly label AI-generated content and requires developers of AI models that implicate national security, national economic security, and public health and safety to share their safety test results and other critical information with the US government.

    President Biden also formed the AI Safety Institute at the National Institute for Standards and Technology, which is part of the Commerce Department. Prior to his election, President-elect Trump pledged to repeal the AI executive order, stating that it “hinders AI Innovation” and that “Republicans support AI Development rooted in Free Speech and Human Flourishing.” Although it remains to be seen how a Trump administration will differ in its treatment of AI, enforcement actions focused on standard causes of action such as fraud and deceptive trade practices are likely to continue, even in the absence of new or more comprehensive federal regulation.

    In Congress, Senator Chuck Schumer has led calls for a comprehensive legislative AI framework, although, to date, that has taken the form of legislative working groups and roadmap documents. (In May 2024, the Bipartisan Senate AI Working Group released a “[r]oadmap for artificial intelligence policy in the United States Senate,” stating that “existing laws, including related to consumer protection and civil rights, need to consistently and effectively apply to AI systems and their developers, deployers, and users.) Yet there has been no federal legislation.

    There has, however, been substantial legislation passed on the state level. In June 2024, Colorado passed its Artificial Intelligence Act, the first state comprehensive framework addressing the development and deployment of AI, which requires developers of “high-risk artificial intelligence” to use reasonable care to protect consumers from the risks of “algorithmic discrimination.” In September 2024, California passed more than a dozen AI-related bills, including measures imposing disclosure requirements on AI companies regarding the datasets used to train their models, requiring healthcare providers to disclose when they use generative AI to communicate with patients, and imposing limits on how healthcare providers and insurers can automate their services. Since 2023, Indiana has created an AI task force, and Illinois, Louisiana, Texas, and West Virginia have established committees on AI. Additionally, New Hampshire has made it a crime to fraudulently use deepfakes and has created a cause of action.

    In the absence of federal legislation and regulation specifically targeting AI, agency officials and prosecutors are regulating AI through the enforcement of existing laws in areas such as consumer protection, financial services, privacy, and civil rights. Enforcement activity thus far has been limited and consistently focused on the impact of AI on individuals, including abuses of AI to perpetrate fraud or deceive consumers.

    In the past year, prosecutors have targeted crimes committed through or with the assistance of AI, rather than scrutinizing the development of the technologies themselves. There has been a particular emphasis on the ways in which AI has been implicated in unfair or deceptive practices and the types of fraudulent schemes commonly prosecuted by both local and federal law enforcement.

    FTC Actions

    On September 25, 2024, the US Federal Trade Commission (FTC) announced a new law enforcement sweep called Operation AI Comply. Lina M. Khan, chair of the FTC, emphasized that “[u]sing AI tools to trick, mislead, or defraud people is illegal” and “there is no AI exemption from the laws on the books.” The initiative specifically targeted operations that either used AI or sold AI technology that could be used in deceptive and unfair ways, as evidenced by the enforcement actions included in the initial rollout of the initiative:

    • DoNotPay, an online subscription service offering assistance with commercial and legal issues, held itself out to be “the world’s first robot lawyer” and settled charges for false or unsubstantiated performance claims. The settlement required the company to pay $193,000 and issue a notice to consumers who subscribed to the service between 2021 and 2023 warning them about the limitations of the law-related features of the service.
    • Ascend Ecom, Ecommerce Empire Builders, and FBA Machine – three separate companies operating online business opportunity schemes – were charged by the FTC for making representations about their AI-powered business models as part of deceptive earnings claims. As a result of these complaints, federal courts temporarily halted each scheme and put the entities under the control of a receiver.
    • Rytr, which marketed and sold an AI writing assistant that produced AI-generated reviews, settled charges for providing its customers with the means to generate false and deceptive written content for consumer reviews.

    In November 2024, the FTC charged Sitejabber, a company offering an AI-enabled consumer review platform that “deceived consumers by misrepresenting that ratings and reviews it published came from customers who experienced the reviewed product or service, artificially inflating average ratings and review counts.” More recently, the FTC has negotiated settlements with two different companies involved in security systems – Evolv Technologies and IntelliVision Technologies Corp. Evolv was alleged to have made false representations about its AI-powered security screening system, claiming that it can detect weapons and ignore harmless personal items, including in sports stadiums, hospitals, and schools. Samuel Levine, the director of the FTC’s Bureau of Consumer Protection, underscored that representations about a technology’s abilities need to be especially accurate when they concern the safety of children. IntelliVision Technologies was alleged to have made deceptive claims about its facial recognition software – specifically that its AI-powered facial recognition software was free of gender and racial bias and that it had one of the highest accuracy rates on the market.

    SEC Actions

    The FTC is not alone in its recently expressed commitment to investigating and applying existing regulatory frameworks to products and services involving or purporting to involve AI. On March 18, 2024, the US Securities and Exchange Commission (SEC) announced that it had settled charges against two investment advisers, Delphia (USA) Inc. and Global Predictions Inc., for making false and misleading statements about their purported use of AI. The firms agreed to settle the SEC’s charges and pay $400,000 in collective civil penalties. The SEC found that Delphia did not have the AI and machine learning capabilities that it claimed. It also found that Global Predictions falsely claimed to be the “first regulated AI financial advisor” and misrepresented that its platform provided “[e]xpert AI-driven forecasts.”

    Gary Gensler, chair of the SEC, explained that the two companies had marketed that they were using AI in certain ways when they were not. Gensler referred to this type of misleading claim as “AI washing” and cautioned that companies are capitalizing on the buzz created by the new technologies and purporting to use them to lure and mislead investors and customers. On January 25, 2024, the SEC issued an Investor Alert “to make investors aware of the increase of investment frauds involving the purported use of artificial intelligence (AI) and other emerging technologies.”

    State Regulator Actions

    Some state regulators have also addressed AI technology through enforcement actions. Most recently, the Texas Attorney General’s Office (AGO) announced a “first-of-its-kind” settlement with a healthcare generative AI company, Pieces Technologies. The settlement resolved allegations that the company had made a series of false and misleading statements about the accuracy and safety of its AI products. According to the Texas AGO, the settlement “highlights the potential for enforcement against AI companies under existing laws that are not specific to AI” and emphasized the importance of “exercising caution in developing claims about an AI product’s efficacy or performance.” This Texas case can also be seen as a warning to companies to understand what their vendors or contractors are doing with respect to AI. Although the Texas AGO targeted the technology provider itself – not the four major Texas hospitals that deployed the technology – the action remains of import to those who use advanced technologies.

    Other state attorneys general have also announced or demonstrated a commitment to act on AI, especially using traditional consumer protection theories. In 2023, 23 state attorneys general, including both Democrats and Republicans, responded to the National Telecommunications and Information Administration (NTIA) request for comment on AI policies and urged NTIA to ensure that “AI systems are valid and reliable, safe, secure, and resilient, accountable and transparent, explainable and interpretable, privacy-enhanced, and fair.”

    Areas of Future Enforcement

    Regulatory activity by the FTC and other agencies also highlights areas of interest for future enforcement. Specifically, the FTC has issued information-seeking orders to eight companies offering surveillance pricing products and services that incorporate data about consumers’ characteristics and behavior. Surveillance pricing refers to the “opaque market” for products sold by third-party intermediaries that “claim to use advanced algorithms, artificial intelligence, and other technologies, along with personal information about consumers – such as their location, demographics, credit history, and browsing or shopping history – to categorize individuals and set a targeted price for a product or service.” The FTC has also expressed interest in AI investments and the partnerships between AI companies, and it has commenced a study of the industry, including information requests to a number of major technology companies.

    Finally, the FTC has expressed interest in the risks of generative AI, which can include chatbots, deepfakes, and voice clones. The agency has urged individuals and companies to consider whether they should be making or selling a synthetic media or generative AI product given the potential opportunities for its misuse; whether all reasonable precautions to mitigate the risks of the product are being taken; whether the technology or product is misleading people about what they are seeing, hearing, or reading, particularly in the context of advertising; and whether the burden is on the consumer to detect AI-generated content. Individuals and companies operating in this space should carefully weigh the FTC’s non-exhaustive list of concerns presented by both the creation and implementation of AI technologies.

    As of now, federal regulations aimed at AI have yet to be issued, but the enforcement actions described above and the interests telegraphed by the FTC and other regulators confirm that companies need to remain apprised of and vigilant about the risks posed by AI technologies, even as they capitalize on its innovative qualities. While the impact of a new but slim Republican majority in Congress remains unclear, the Trump administration is expected to approach regulatory enforcement of AI with a lighter touch. This is particularly true given the administration’s announcement of tech investor David Sacks as the White House “AI & Crypto Czar.” Nevertheless, bipartisan interest in the AI space and recent enforcement trends indicate that there will continue to be a focus on AI abuses under fraud and deceptive trade practices theories.

    Authors

    Sagar K. Ravi

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Theresa Maria Babendreier

    Associate

    Washington, DC

    More insights

  • Crypto-Assets

    Crypto-Assets

    ARTICLE

    Crypto-Assets

    2025

    Read time: 2 min

    Key takeaways
    Overview

    Renate Prinz and Annabelle Juliette Rau co-authored the commentary “Crypto-Assets” published by Beck Verlag.

    The work highlights the key requirements and considerations for crypto-assets in Germany, including the new Regulation on Markets in Crypto-assets (MiCAR) and the DLT pilot regulation. Our co-authors deal with the licensing of crypto asset service providers and their conduct of business obligations. You can view the complete contents in Beck’s commentary.

    In depth
    Authors

    Annabelle Juliette Rau

    Associate

    Cologne

    More insights

  • Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary

    Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary

    ARTICLE / CLIENT ALERT

    Corporate Transparency Act Update: Government Challenges Nationwide Preliminary Injunction & FinCEN Clarifies That Reports Are Voluntary

    December 18, 2024

    Read time: 5 min

    Key takeaways
    Overview

    This Alert serves to update clients on the recent legal developments related to the Corporate Transparency Act (“CTA”) and its implementing regulation (31 C.F.R. §1010.380 (“Reporting Rule”)) since our prior Alert on Dec. 4, 2024.[1] At this time, none of the recent developments relating to the nationwide preliminary injunction concerning the CTA and the Reporting Rule change our view that filing of beneficial ownership information reports (“BOI Reports”) is voluntary while the nationwide preliminary injunction remains in place. In other words, there is no requirement to submit or update BOI Reports while the nationwide preliminary injunction is in effect. Given the future uncertainty however, we recommend that clients continue to prepare for anticipated BOI Report filings in the event the nationwide preliminary injunction is lifted, stayed or altered.

    Since Judge Amos L. Mazzant of the US District Court for the Eastern District of Texas issued a Memorandum Opinion and Order (the “Order”) preliminarily enjoining enforcement of the CTA and Reporting Rule, the US Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) has issued a statement confirming that filing of BOI Reports is voluntary as long as the nationwide preliminary injunction remains in effect. In addition, the government appealed the Order to the US Court of Appeals for the Fifth Circuit, filed a motion requesting that Judge Mazzant stay the Order pending appeal and requested that the Fifth Circuit stay the Order pending final adjudication of the appeal. We discuss each of these developments below.

    FinCEN Statement

    On Dec. 7, 2024, FinCEN issued a statement advising that “reporting companies are not currently required to file beneficial ownership information with FinCEN and are not subject to liability if they fail to do so while the [O]rder remains in force.” The statement also advised that “reporting companies may continue to voluntarily submit beneficial ownership information reports.”

    Nationwide Preliminary Injunction Updates

    On Dec. 5, 2024, the government appealed the Order to the Fifth Circuit.[2] On Dec. 11, 2024, the government filed a motion with Judge Mazzant asking him to stay enforcement of the Order pending the result of the Fifth Circuit appeal. Following briefing from the parties, Judge Mazzant denied the motion to stay on Dec. 17.

    On Dec. 13, 2024, the government also filed an emergency motion with the Fifth Circuit seeking a stay of the Order pending appeal. In the Fifth Circuit stay motion, the government requested a ruling no later than Dec. 27, 2024, to ensure that reporting companies “can be made aware of their obligation to comply before January 1, 2025.” On the same day, the Fifth Circuit advised the parties that the opposition to the government’s stay motion is due Dec. 17 and the government’s reply in support of its motion to stay is due Dec. 19. Plaintiff-appellees filed their opposition to the government’s motion on Dec. 17. The Fifth Circuit has not ruled on the government’s stay motion as of the date of this Alert.

    In both stay motions, the government requested that, at a minimum, the Order should be stayed pending appeal with regard to reporting companies that are not parties to the litigation. In requesting a stay, the government restated its position that the CTA is constitutional. The government also argued that absent a stay, the government’s significant outreach efforts would be negated at a critical juncture for CTA implementation and efforts of the US to fulfill international standards for countering money laundering and terrorist financing would be stymied.

    What’s Next?

    We will continue to monitor for developments related to this case and whether the Justice Department, the Treasury Department or FinCEN issues any additional guidance in order to assist clients in navigating their CTA obligations. Clients who have not yet filed BOI Reports may refrain from filing BOI Reports until additional guidance is issued by the government or either Judge Mazzant or an appellate court decides whether or not to stay, narrow or limit the nationwide preliminary injunction. Clients who defer filing BOI Reports should nonetheless continue to prepare for anticipated BOI Report filings in the event the preliminary injunction is lifted, stayed or altered.

     

    Authored by Melissa G.R. Goldstein,  Betty Santangelo, Michael S. Didiuk, Jessica Romano and Kyle B. Hendrix.

    For assistance in navigating the CTA’s reporting requirements, please contact one of the authors or your attorney at Schulte Roth & Zabel.


    [1] For more information, please see our prior Alert “Corporate Transparency Act Update: Nationwide Preliminary Injunction Enjoining Enforcement.”

    [2] Texas Top Cop Shop, Inc. v. Garland, No. 24-40792 (5th Cir. Dec. 9, 2024).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. © 2024 Schulte Roth & Zabel LLP. All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Kyle B. Hendrix

    Associate

    Washington, DC

    More insights

  • Peering Into the Crystal Ball: Crypto Enforcement in a Second Trump Term

    Peering Into the Crystal Ball: Crypto Enforcement in a Second Trump Term

    ARTICLE / REPORT / US POLICY

    Peering Into the Crystal Ball: Crypto Enforcement in a Second Trump Term

    December 17, 2024

    Read time: 3 min

    Overview

    In November 2021, at the height of cryptocurrency’s “bull run,” the market capitalization for crypto reached a record of nearly $3 trillion. Just a year later, and shortly after FTX petitioned for Chapter 11 bankruptcy protection in November 2022, however, this value had plummeted by 75%. While there were many factors other than FTX’s collapse that led to this significant decline, FTX’s failure was a watershed moment for government enforcement efforts across the crypto industry.

    This Special Report explores how the government has pursued crypto companies and individuals following the collapse of FTX and how those enforcement priorities may change and impact crypto’s future under the Trump administration starting January 2025. In particular, we analyze enforcement priorities that have emerged over the last two years since FTX, including actions related to (1) failure to register securities, (2) fraudulent offerings, (3) money laundering and mixers, and (4) market manipulation and liquidity pools. With the reelection of President-elect Donald J. Trump – who has signaled an intention to substantially reduce regulatory scrutiny over crypto – these enforcement priorities, and the governmental entities and units advancing them, will undoubtedly shift. After our analysis of each priority, we provide commentary on what to expect from the Trump administration going forward.

    In depth
    Tabs

    Joseph B. Evans

    Partner

    New York – One Vanderbilt Avenue

    Sagar K. Ravi

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Joseph M. Aminov

    Associate

    New York – One Vanderbilt Avenue

    Daniel H. Kaltman

    Associate

    New York – One Vanderbilt Avenue

    More insights
    Endnotes

  • CDRH Looks Ahead With FY 2025 Proposed Guidance Agenda

    CDRH Looks Ahead With FY 2025 Proposed Guidance Agenda

    ARTICLE / CLIENT ALERT

    CDRH Looks Ahead With FY 2025 Proposed Guidance Agenda

    December 13, 2024

    Read time: 8 min

    Key takeaways
    Overview

    On October 10, 2024, the US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) announced its agenda of proposed guidance documents to be published or developed in the 2025 fiscal year (FY). The proposed guidance documents span a wide range of device topics, including real-world evidence in the device submission process, artificial intelligence (AI)-enabled functionalities in medical devices, and enforcement priorities following the regulation of laboratory developed tests (LDTs). Notably, this agenda was released by the Biden administration. The new administration will revisit the agenda and likely issue an updated version with its own priorities in early 2025.

    In depth

    The proposed documents for the agenda are divided into three tiers of descending priority:

    • The A-list, representing the agency’s top priorities for CDRH.
    • The notably shorter B-list.
    • The “Under Construction” list for guidance documents that CDRH intends to develop as resources permit and that are not on the A- or B-list.

    The table below details the most important guidances included on CDRH’s regulatory agenda:

    Guidance Description Other Resources
    Laboratory Developed Tests: Enforcement Discretion Policy Regarding Special Controls A final guidance document on the A-list that will respond to a 2024 final rule, which in part announced an intent to phase out FDA’s previous general enforcement discretion approach to LDTs. McDermott has previously tracked FDA’s LDT enforcement policy; see our On the Subject that discusses these policies in greater depth.
    Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program (Revision) A final guidance document on the A-list that will describe best practices for the Q-Submission Program, which comprises approved, manufacturer-FDA interactions such as pre-submissions, submission issue requests, study risk determinations, informational meetings, and premarket approval day 100 meetings. The guidance will also detail various uncategorized and informal interaction types that may be available to device manufacturers. FDA previously issued draft guidance on March 15, 2024.
    Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (Revision) A final guidance document on the A-list that will describe FDA’s current position on the use of real-world data (which includes clinically relevant electronic health records data and medical claims data) during the submission process. The document will also discuss the salience of real-world data in the performance of FDA’s regulatory responsibilities. FDA previously issued draft guidance on December 19, 2023.
    Marketing Submission Recommendations for a Predetermined Change Control Plan for AI-Enabled Device Software Functions A final guidance document on the A-list that will detail FDA’s current thinking on how manufacturers of devices with AI or machine-learning capabilities should structure a premarket control plan when drafting a marketing submission for a device with pre-planned modifications. A draft guidance document published in April 2023 suggested that manufacturers include a description of planned modifications, their modification protocol, and a modification impact assessment. FDA issued this final guidance earlier than anticipated, on December 3, 2024.
    AI-Enabled Device Software Functions: Lifecycle Management Considerations and Pre-Market Submission Recommendations A draft guidance document on the A-list responding to FDA’s recent interest in applying a “lifecycle management framework” to the regulation of AI-enabled medical devices. The Director of FDA’s Digital Health Center of Excellence, Troy Tazbaz, published a blog post on this topic in July 2024. In November 2024, FDA’s Digital Health Advisory Committee engaged in a panel discussion about total lifecycle considerations for technologies leveraging generative AI.
    Enforcement Discretion Policy for Certain LDTs for Unmet Needs: Frequently Asked Questions A draft guidance document on the A-list.
    In Vitro Diagnostics: Labeling A draft guidance document on the A-list that would detail FDA’s expectations and provide recommendations for the labeling of in vitro diagnostic tests. In May 2024, FDA published a final rule that clarified the Federal Food, Drug, and Cosmetic Act’s application to in vitro diagnostic products, including when they are manufactured by a laboratory. FDA held a webinar on complying with labeling requirements for in vitro diagnostic tests in September 2024.
    Policy for Regulatory Status of Device Software Functions (Revision) A draft guidance document on the B-list that would revise a final guidance document published in 2022, titled “Policy for Device Software Functions and Mobile Medical Applications.” The current iteration of this guidance highlights FDA’s intention to focus its oversight on mobile medical apps, defined as devices used as an accessory to regulated medical devices or to transform a mobile platform into a regulated medical device.
    Clinical Evidence Considerations for Digital Mental Health Treatment Devices, Including Computerized Behavioral Therapy Devices A draft guidance document on the Under Construction list.
    Best Practices for Selecting a Predicate Device to Support a Premarket Notification (510(k)) Submission A final guidance document on the Under Construction list that will assist manufacturers in selecting an appropriate predicate device for their 510(k) submission. In a previously published draft guidance document, the four best practices were listed as:

    • Basing a 510(k) submission on a predicate device that has been cleared via well-established methods
    • Selecting a device that has remained safe and effective consistently in its intended use environment
    • Refraining from selecting a device that has known or emerging use- or design-related safety issues
    • Refraining from selecting a device that has been subject to a design-related recall.
    Recommendations for the Use of Clinical Data in Premarket Notification (510(k)) Submissions A final guidance document on the Under Construction list that will clarify when manufacturers may need to provide clinical data to establish that a device is substantially equivalent to a predicate device. In its previously published draft guidance, FDA highlighted four scenarios where such submissions may be appropriate, including those where clinical data would be useful to evaluate differences between the two devices’ indications for use.
    3D Printing Medical Devices at the Point of Care A draft guidance document on the Under Construction list. CDRH released a discussion paper on this topic in 2021, identifying the unique challenges presented by the 3D printing of medical devices in the point of care context and enumerating several principles to be considered when structuring a related regulatory framework. These principles included employing a risk-based approach to regulation, understanding the varying technical capabilities of facilities, and leveraging the least burdensome approach to ensure printed devices are safe and effective.
    General/Specific Intended Use (Revision) A draft guidance document on the Under Construction list that would revise final guidance published in 1998 on the same topic. The current iteration of this guidance details the criteria that FDA uses when determining whether a device meets substantial equivalence requirements for general versus specific uses. Among other criteria, the list includes a specific use’s potential risks, its potential public health impact, and whether there is clinical evidence that supports the specific use.
    Substantial Equivalence With Limitations: 510(k) Devices (Revision) A draft guidance document on the Under Construction list that would revise a final guidance document published in 2002, titled “Determination of Intended Use for 510(k) Devices.” The current iteration of this guidance specifies how FDA determines the intended use of a device for purposes of a substantial equivalence analysis. FDA looks to the proposed labeling of the device as well as the likelihood that the device could be used for a harmful purpose beyond its proposed label.

    CDRH also anticipates that certain regulations impacting medical devices may be finalized in 2025:

    • A proposed rule that would create procedures for placing a clinical hold and suspending a clinical investigation of a medical device.
    • A proposed rule to classify minimally manipulated allograft hearth valves as Class III devices.
    • A final rule to classify human leukocyte antigen, human platelet antigen, and human neutrophil antigen devices into Class II with special controls.
    • A final rule and companion proposed rule that would amend 21 C.F.R. part 807 to correct inconsistencies related to registration and listing requirements for human cells, tissues, or cellular or tissue-based products regulated as devices and would require that they follow 21 C.F.R. part 807 registration and listing procedures.

    In addition to inviting general comments on the substantive topic areas covered by each of the proposed guidance documents, CDRH requests stakeholder comments on how the guidance documents should be prioritized internally.

    If you are interested in submitting comments to CDRH or have questions about how CDRH’s agenda for FY 2025 could impact your business, please contact a member of McDermott’s Food, Drug & Medical Device Regulatory Group.

    Authors

    James R. Ravitz

    Partner

    Washington, DC

    Paul S. Gadiock

    Partner

    San Francisco

    Michael W. Ryan

    Partner

    Washington, DC

    Jeff Weinstein

    Counsel

    Washington, DC

    Marissa Hill Daley

    Law Clerk

    Washington, DC

    Henry Fisher

    Associate

    Washington, DC

    Jae Hyun Lee

    Associate

    New York – One Vanderbilt Avenue

    More insights

  • HHS Letter Reiterates Expectations for Language Accessibility

    HHS Letter Reiterates Expectations for Language Accessibility

    ARTICLE / CLIENT ALERT

    HHS Letter Reiterates Expectations for Language Accessibility

    December 12, 2024

    Read time: 5 min

    Key takeaways
    Overview

    On December 5, 2024, the US Department of Health and Human Services (HHS) Office for Civil Rights (OCR) issued a “Dear Colleague” letter reiterating obligations that covered entities have under the May 2024 final rule related to language access requirements under Section 1557 of the Affordable Care Act. Section 1557 prohibits discrimination on the basis of race, color, national origin, sex, age, or disability in covered health programs and activities. The final rule strengthened many protections against discrimination in healthcare, including rules for providing language assistance to individuals with limited English proficiency (LEP) or disability. This Dear Colleague letter had the goal of outlining key requirements to ensure that covered entities provide meaningful language access to individuals in time for the June 5, 2025, deadline for full implementation.

    In depth

    HHS used the letter to emphasize its expectations for compliance with key language access requirements, including the following:

    • Definition of an Individual With LEP. Covered entities should not assume that because an individual speaks English, the individual is proficient in English. An individual may be competent in speaking English but limited in reading or writing English. The technical nature of healthcare makes it particularly important for covered entities to ensure individuals with LEP have a full understanding of both written and spoken communications.
    • Definition of Meaningful Access. Providing meaningful access to individuals with LEP includes consideration of cultural competencies, such as variations in dialects and expressions that may influence accurate translations.
    • Language Assistance Services. Language assistance services must be provided free of charge and protect a patient’s privacy and independent decision-making abilities. Interpreters must convey information in such a way that patients understand the consequences of consenting to or rejecting treatment, and in a setting that preserves patient privacy.
    • Use of Qualified Interpreters and Translators. Interpreters and translators must maintain patient confidentiality and meet certain regulatory qualifications that demonstrate proficiency in writing and understanding English and at least one non-English language. They also must demonstrate that they can translate effectively, accurately, and impartially to and from English and the non-English language, including any specialized vocabulary and terms, while retaining the tone, sentiment, and emotional level of the original statement. They must adhere to principles of ethics. If an interpreter and individual with LEP know each other, generally a different interpreter should be requested. Covered entities may not require individuals with LEP to provide – or pay for – their own interpreters.
    • Use of Bilingual Staff. OCR emphasized that relying on an employee who self-identifies as proficient in the target language is not sufficient to meet the Section 1557 translation requirements.
    • Use of Machine Translation. If a covered entity uses machine translations for critical documents, the translations must be reviewed by a qualified human translator to ensure accuracy as soon as practicable. OCR appears to be less concerned about using machine translation when there is no risk of impacting the rights of individuals being served, although the translation should include a warning that it may contain errors.
    • Emergency Circumstances. Covered entities should generally not rely on unqualified individuals to provide interpretation or translation services except in two circumstances. First, an unqualified adult or minor may temporarily provide language assistance services while a qualified interpreter is being located if the circumstances involve an imminent threat to the safety or welfare of an individual or the public. In such an instance, when a qualified adult arrives, that person should confirm or supplement the initial communications. Second, if an individual with LEP specifically and privately requests that an unqualified adult (but not a minor) serve in this role, a qualified interpreter should confirm the nature of the request and that reliance is appropriate in the circumstance.
    • Notices of Nondiscrimination and Availability. Annually, covered entities must provide a Notice of Nondiscrimination and a Notice of Availability of language assistance and other services to participants, upon request, and must post such notices in physical locations and on the entity’s website, as applicable. The Notice of Availability must also be provided in significant written communications, such as applications, notices of eligibility, and communications related to public health emergencies.
    • Language for Notice of Availability. OCR reiterated that the Notice of Availability must be provided in English and at least the 15 most commonly spoken languages by individuals with LEP in the relevant state or states of the covered entity’s operations. For entities operating in multiple states, the Notice of Availability must reflect the most commonly spoken non-English language in each of the applicable states. Top languages can be determined in the “Limited English Proficiency.”

    While the Dear Colleague letter is not itself legally binding, such letters are infrequently issued, suggesting that HHS is focused on applying and enforcing the language access provisions of Section 1557. Whether this level of focus remains a priority for the next presidential administration is yet to be seen. Changes in Section 1557’s language access regulations from the Obama administration to the first Trump administration to the Biden administration were largely administrative rather than substantive, so covered entities would be well advised to continue efforts to implement Section 1557’s language access requirements consistent with HHS’s letter by July 5, 2025.

    Authors

    Emily R. Curran

    Associate

    Washington, DC

    More insights

  • The EU Corporate Sustainability Reporting Directive: What Non-EU Multinational Companies Need to Know

    The EU Corporate Sustainability Reporting Directive: What Non-EU Multinational Companies Need to Know

    ARTICLE / CLIENT ALERT

    The EU Corporate Sustainability Reporting Directive: What Non-EU Multinational Companies Need to Know

    December 11, 2024

    Read time: 13 min

    Key takeaways
    Overview

    Although political sentiment against mandatory sustainability reporting by business entities has grown in Europe (similar to the anti-ESG backlash in the United States), the European Commission (EC) has not backed down. On September 25, 2024, the EC initiated formal proceedings against 17 EU Member States[1] for failing to timely transpose the European Union’s Corporate Sustainability Reporting Directive (CSRD) into their national laws by the July 2024 deadline, creating compliance uncertainty for entities that will be required to report under the CSRD.

    The EC noted that without transposition of the CSRD throughout the EU, harmonization of sustainability reporting will be impaired, hurting the ability of investors to evaluate comparable metrics on the sustainability performance of companies when making investment decisions. The 17 noncompliant member states were given two months to respond and complete their transpositions.

    As member states transpose the CSRD into their national laws, variations are enacted in the rules as adopted by each state. In some member states, the disclosure requirements are more rigorous than required by the CSRD.

    While transposition efforts progress at varying paces, the European Financial Reporting Advisory Group (EFRAG) has issued several European Sustainability Reporting Standards (ESRS) and related implementation guidance that specify and clarify the sustainability information companies will need to report on in accordance with the CSRD. Despite the volume of guidance issued, companies face substantial uncertainty on numerous reporting issues.

    Notwithstanding the delays in transposition, the first deadlines to meet the CSRD’s reporting requirements are fast approaching. Companies with a significant presence in the EU will need to evaluate the mechanisms they have in place for collecting and reporting sustainability information on a global scale. Certain large non-EU companies will need to make reports in compliance with the CSRD as soon as 2025, so data collection should have begun this year. Beginning in 2026, certain large EU subsidiaries of non-EU companies must report data for fiscal years beginning on or after January 1, 2025.

    This advisory focuses on applying the CSRD to non-EU companies. Adopted in November 2022, the CSRD imposes disclosure obligations on companies organized within the EU Member States and on two categories of companies organized outside of the EU: companies with significant operations within the EU and companies listed on EU exchanges.

    In depth

    Who Reports

    Categorization Based on Company Size

    The CSRD will require reporting by certain companies based on their size. A company’s size – Large, Medium, Small, or Micro – is determined using balance sheet, revenue, and employee thresholds, all on a consolidated basis (as updated to account for inflation in late 2023):

    Balance Sheet Total Revenue Average Number of Employees During Financial Year
    Large company2 (meets two of three criteria) Greater than €25 million Greater than €50 million Greater than 250
    Medium company3 (meets two of three criteria) Less than €25 million Less than €50 million Less than 250
    Small company4 (meets two of three criteria) Less than €5 million Less than €10 million Less than 50
    Micro company5 (meets two of three criteria) Less than €450,000 Less than €900,000 Less than 10

    EU Subsidiaries of Non-EU Companies

    EU subsidiaries of non-EU companies that (i) are Large, (ii) have securities listed on an EU exchange, and (iii) employ more than 500 individuals are required to report data for fiscal years beginning on or after January 1, 2024. This means data collection should have begun this year and reports will be filed with the applicable authorities in 2025.

    Other EU subsidiaries of non-EU companies that are Large must report data for fiscal years beginning on or after January 1, 2025. This means the first reports will be filed with the applicable authorities in the EU Member State of domicile in 2026 and data collection will need to begin as early as January 1, 2025. It is worth noting that the reporting and size determination occur on a consolidated basis and would sweep in activities of non-EU entities housed under an EU parent company. Accordingly, a holding company organized in an EU Member State (e.g., Ireland or Luxembourg) would include all its subsidiaries in its calculations to determine size and include information about the operations conducted by all its subsidiaries in its CSRD report.

    As discussed below, the CSRD applies to Small and Medium “undertakings” (i.e., companies) only if they (i) have securities listed on an EU exchange or (ii) are “public interest entities.” Micro companies are not required to report under the CSRD.

    Non-EU Companies With Significant EU Operations

    The EU operations of non-EU companies will trigger CSRD reporting obligations (at the level of the ultimate parent on a consolidated basis) if the net turnover of those operations exceeds a multiyear net turnover threshold. For example, a US organized multinational corporation subject to CSRD reporting will be required to report the consolidated results of its global operations. When a non-EU company’s total net turnover generated in the EU on a consolidated basis exceeds €150 million in two consecutive fiscal years, the non-EU company will be subject to CSRD reporting requirements if the non-EU company has either an EU-domiciled subsidiary that is subject to CSRD reporting or a branch in the EU with net turnover of more than €40 million.

    Operating Through a Branch

    Non-EU companies operating in the EU through a “branch” office (i.e., without a subsidiary organized within the EU) will trigger reporting obligations if the branch achieved a net turnover of €40 million in the most recent fiscal year.

    Operating Through One or More Subsidiaries

    Non-EU companies operating in the EU through one or more subsidiaries will trigger reporting obligations if one or more subsidiaries is a Large, Medium, or Small company in which there is a public interest.[6] There is a public interest in (i) entities traded on the regulated market of any EU Member State, (ii) credit institutions, (iii) insurance companies, and (iv) entities designated as a public interest entity by any EU Member State because of the nature of its business, size, or number of employees.

    What Needs to Be Reported and When

    Where CSRD reporting is triggered for a non-EU company with significant EU operations, consolidated reporting at the ultimate parent level is required for fiscal years starting on or after January 1, 2028, meaning data collection would need to begin in 2028 with reports due in 2029. The CSRD requires that management reports contain “information necessary to understand” the company’s impact on sustainability matters and “information necessary to understand” how sustainability matters impact the company’s growth, performance, and market position.[7] These reports must contain the same information as the reports prepared by non-EU companies with securities listed on an EU exchange (discussed below), but non-EU companies with significant EU operations reporting under the CSRD may omit certain items related to the resilience of the business regarding sustainability risks and sustainability-related opportunities.[8]

    This information must be reported based upon short-, medium-, and long-term time horizons and comply with the forthcoming sustainability reporting standards for non-EU companies (NESRS).[9] The deadline for NESRS to be adopted is June 30, 2026, with public comment expected to begin in early 2025. Discussion drafts were published by EFRAG on November 18, 2024.

    Non-EU Companies With Securities Listed on an EU Exchange

    When Do Reporting Obligations Begin?

    The CSRD requires reporting for non-EU organized companies with securities listed on an EU-regulated exchange. These companies must prepare reports in accordance with the CSRD and the ESRS. The timeframe for reporting is determined by the “size” of the company (see the table above regarding size classifications), using the criteria below.

    Compliance Timeline for Non-EU Organized Companies With EU Listings
    Compliance Begins:
    January 1, 2024
    Initial Reports Due:
    2025
    Issuers that are Large companies (on a consolidated basis) and have more than 500 average employees during the fiscal year
    Compliance Begins:
    January 1, 2025
    Initial Reports Due:
    2026
    Issuers that are Large companies (on a consolidated basis) with fewer than 500 average employees in the prior fiscal year
    Compliance Begins:
    January 1, 2026
    Initial Reports Due:
    2027
    Issuers that are Small or Medium companies (except Micro companies)Issuers that are Small, noncomplex credit institutions, captive insurance companies, or captive re-insurance companies that are (i) Large companies or (ii) certain Small or Medium companies in which there is a public interest

    What Sustainability Information Must Be Reported

    The CSRD requires that management reports contain information “necessary to understand the company’s impact on sustainability matters, and information necessary to understand how sustainability matters” impact the company’s development, performance, and position.[10] This information must be reported based upon short-, medium-, and long-term time horizons and comply with applicable ESRS.[11] At a minimum, reports must contain certain information required by the CSRD, such as:

    • A brief description of the company’s business model and strategy, including:
      • The resilience of the business model and strategy concerning risks related to sustainability matters
      • Opportunities for the company related to sustainability matters
      • The company’s plans, including implementing actions and related financial and investment plans, to ensure its business model and strategy are compatible with the transition to a sustainable economy. The company’s plans should also align with the limiting of global warming to 1.5°C in line with the Paris Agreement, the goal of achieving climate neutrality by 2050 (as established in Regulation (EU) 2021/1119) and, where relevant, the exposure of the company to coal-, oil- and gas-related activities
      • How the company’s business model and strategy take into consideration the interests of the company’s stakeholders and the company’s impact on sustainability matters
      • How the company’s strategy has been implemented as it relates to sustainability matters
    • A description of the time-bound targets related to sustainability matters set by the company, including (where appropriate) absolute greenhouse gas (GHG) emission reduction targets for 2030 and 2050, a description of the progress the group has made toward achieving said targets, and whether the company’s targets related to environmental factors are based on conclusive scientific evidence, including GHG emissions[12], as set forth below:
    Emission Content
    Scope 1 GHG emissions
    • Gross Scope 1 GHG emissions in metric tonnes of CO2eq
    • Percentage of Scope 1 GHG emissions from regulated emission trading schemes
    Scope 2 GHG emissions
    • Gross location-based Scope 2 GHG emissions in metric tonnes of CO2eq
    • Gross market-based Scope 2 GHG emissions in metric tonnes of CO2eq
    Scope 3 GHG emissions
    • GHG emissions in metric tonnes of CO2eq from each Scope 3 category that is a priority for the company
    Total GHG emissions
    • Sum of Scopes 1, 2, and 3 GHG emissions
    • A description of the role of the administrative, management, and supervisory bodies with regard to sustainability matters, as well as a description of their expertise and skills in relation to fulfilling said role or the access such bodies have to such expertise and skills
    • A description of the company’s policies in relation to sustainability matters
    • Information about the existence of incentive schemes linked to sustainability matters, which are offered to members of the administrative, management, and supervisory bodies
    • A description of:
      • The due diligence process implemented by the company with regard to sustainability matters and, where applicable, in line with EU requirements on companies to conduct a due diligence process
      • The principal actual or potential adverse impacts connected with the company’s own operations and value chain, including its products and services, business relationships, and supply chain, actions taken to identify and monitor said impacts, and other adverse impacts the company is required to identify pursuant to other EU requirements to conduct a due diligence process
      • Any actions taken by the company to prevent, mitigate, remediate, or bring an end to actual or potential adverse impacts and the result of such actions
    • A description of the principal risks to the company related to sustainability matters, including the company’s principal dependencies on those matters, and how the company manages those risks
    • Indicators relevant to the disclosures referred to in the points above.[13]

    ESRS and Double Materiality

    The ESRS, as promulgated by EFRAG, forms the backbone of the reporting framework with which CSRD reports will need to comply. The first set of ESRS is sector agnostic, consists of two cross-cutting standards – ESRS 1 and ESRS 2 – and applicable to all subject matters and 10 standards covering specific ESG subject matters:

    • ESRS E1 (Climate Change)
    • ESRS E2 (Pollution)
    • ESRS E3 (Water and Marine Resources)
    • ESRS E4 (Biodiversity and Ecosystems)
    • ESRS E5 (Resource Use and Circular Economy)
    • ESRS S1 (Own Workforce)
    • ESRS S2 (Works in the Value Chain)
    • ESRS S3 (Affected Communities)
    • ESRS S4 (Consumers and End-Users)
    • ESRS G1 (Business Conduct).

    EFRAG intends for the ESRS to be interoperable with sustainability reporting standard promulgated by both the Global Reporting Initiative[14] and the International Financial Reporting Standards (IFRS) Foundation’s International Sustainability Standards Board (ISSB).[15] EFRAG is currently in the process of drafting sector-specific sets of the ESRS and the NESRS.

    Undergirding the application of the ESRS is the concept of double materiality set forth in ESRS 1, which applies across all ESRS (other than ESRS 2, which requires certain matters to be reported irrespective of materiality). This double materiality is either “financial materiality” or “impact materiality.”

    ESRS 1 defines a sustainability matter as financially material “if it triggers or could reasonably be expected to trigger material financial effects on the undertaking.” While “[a] sustainability matter is material from an impact perspective when it pertains to the undertaking’s material actual or potential, positive or negative impacts on people or the environment over the short-, medium- or long-term.”

    The double materiality standard set out in ESRS 1 is a break from more investor-focused materiality standards used in other sustainability reporting frameworks (e.g., those of the ISSB’s Sustainability Accounting Standards Board). Accordingly, EFRAG has published additional guidance in the form of EFRAG IG 1 (Materiality Assessment) on the application of double materiality.

    Forthcoming Assurance Requirements

    The CSRD contemplates requiring assurance of sustainability reports prepared in accordance with the CSRD and applicable sustainability reporting standards. The CSRD requires the EC to adopt delegated acts setting standards for “limited” assurance of sustainability reports by October 1, 2026, and for reasonable assurance of sustainability reports by October 1, 2028.

    How Non-EU Companies Should Prepare

    Assess Applicability and Follow Transposition

    Applicability of CSRD reporting requirements and the timeframe for filing an initial report is based on the financial performance and legal structure of the non-EU parent and on the subsidiary or branch office. While financial performance is never guaranteed, companies can use their current financial performance to determine whether reporting requirements are likely to apply to any entities within their organizational structure. EU Member States were given until July 2024 to transpose CSRD requirements into their national laws, with the ability to add additional requirements. As noted at the outset, several EU Member States have not yet transposed the CSRD requirements into national law. Identifying where your EU operations exist (both the physical presence and the jurisdictions of holding companies) and which EU Member State’s national laws to follow will prove useful in complying with the forthcoming requirements. With the initial reports for Large EU companies without an EU listing due in 2026 (with data collection needing to begin in 2025), timing is key.

    Build Competency Now

    Non-EU companies that trigger reporting requirements under the CSRD may also trigger reporting requirements in the United Kingdom, California, and other jurisdictions across the globe. To successfully align reporting across varying jurisdictions and different reporting frameworks, knowledgeable, cross-functional teams will need to collect, refine, and produce the underlying information necessary to comply with these reporting requirements.

    Align Assurance Providers and Other Advisors

    Non-EU companies will be required to make their reports under the CSRD with the opinion of a third-party assurance provider. These providers must be authorized by the national law of the non-EU company’s jurisdiction of organization or of an EU Member State to give an opinion on sustainability information.[16]

    Authors

    David A. Cifrino

    Counsel

    Boston

    Stephen Aber

    Law Clerk

    Boston

    Dr. Philipp Grenzebach

    Partner

    Düsseldorf, Frankfurt

    Annabelle Juliette Rau

    Associate

    Cologne

    More insights

  • Colorado Advances Privacy Act Regulations

    Colorado Advances Privacy Act Regulations

    ARTICLE / CLIENT ALERT

    Colorado Advances Privacy Act Regulations

    December 10, 2024

    Read time: 3 min

    Key takeaways
    Overview

    On December 5, 2024, the Colorado Department of Law (Department) adopted an amended draft of its latest proposed Colorado Privacy Act (CPA) regulations. This set of amended regulations follows a public comment period that concluded with a public hearing held on November 7, 2024. The Department has also provided a cover letter explaining how the regulations were revised based on feedback received during the comment period.

    In depth

    As a refresher, the proposed regulations:

    1. Require any controller (including employers) that collects biometrics to give a pre-collection notice to the data subject;
    2. Impose new biometrics collection obligations on employers;
    3. Require controllers to obtain consent to process the personal data of minors (consumers under age 18); and
    4. Introduce methods by which companies can seek regulatory guidance from the Colorado attorney general (AG).

    The amended regulations introduce some implementation-friendly clarifications, including providing that:

    • A controller’s biometric notice may be included in its general privacy notice;
    • Consent is only required when processing the personal data of a consumer whom the controller “actually knows or willfully disregards” is a minor;
    • Employers are only required to “refresh” consent to collect biometrics in certain limited scenarios; and
    • Submitting a data protection assessment when seeking an opinion letter from the AG does not constitute a waiver of attorney-client privilege, and assessments required under the CPA are exempt from public inspection under the Colorado Open Records Act.

    As the final step in the rulemaking process, the Department has requested a formal opinion on the amended regulations from the AG. The regulations will be filed with the Colorado secretary of state after a formal opinion is issued, and the regulations will become effective 30 days after they are published in the state register. Given the short runway after the regulations are published, businesses subject to the CPA should begin preparing to comply with the newly adopted draft of the CPA regulations.

    If you have questions or need assistance preparing for the new state consumer laws, please contact your regular McDermott lawyer or reach out to the authors.

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights

  • Update on Exit Tax for Investment Shares

    Update on Exit Tax for Investment Shares

    ARTICLE / CLIENT ALERT

    Update on Exit Tax for Investment Shares

    December 5, 2024

    Read time: 6 min

    Key takeaways
    Overview

    Exit taxes will apply to private investors in investment funds who leave Germany and have purchased investment shares priced at a minimum of €500,000, including common exchange-traded funds (ETFs). This was decided by the German Federal Parliament (Bundestag) and the German Federal Council (Bundesrat) via the Annual Tax Act 2024 (Jahressteuergesetz 2024).

    The new regulation will apply starting January 1, 2025. However, investors can ensure that the exit tax does not apply or is only payable in installments – even after January 1, 2025. Similar rules on exit taxes are already applied to corporations and business investors, such as entrepreneurs. The new rule does not directly affect custodian banks and financial investment management companies.

    In depth

    The New Rules: An In-Depth Review

    Below, we outline the key aspects of the new regulation for holders of investment shares who leave or transfer their shares outside of Germany.

    Introductory Example

    A taxpayer has paid into an ETF savings plan with €2,000 per month for 22 years. After 22 years, they have acquisition costs totaling €528,000. The value of his ETF shares now amounts to €828,000. If they leave Germany and move abroad, the increase in value of €300,000 is generally subject to the new taxation. In the usual case of an equity fund, income tax of more than €50,000 would become due – without being able to pay it out of an actual cash inflow (dry income).

    Affected Investment Shares

    The affected investors are private individuals in Germany who have acquired investment shares with a purchase price of at least €500,000, such as ETFs, equity funds or bond funds, or at least 1% of the shares of an investment fund (Section 19, paragraph 3, sentence 2 of the German Investment Tax Act (Investmentsteuergesetz) in its new version, InvStG nF). Private investors who have invested in (rarer) so-called special investment funds are also affected, regardless of the amount of their share (Section 49, paragraph 5, sentence 1, InvStG nF). Both shares held directly and those held through asset-managing partnerships are included.

    Affected Investors and Taxation Triggers

    To be subject to the exit tax, the person leaving must have lived in Germany for at least seven years in the 12 years prior to leaving or must have had a residence in Germany. A move abroad is often deemed to have occurred when the last residence in Germany is given up.

    The exit tax is also due if investment shares are given away or inherited and the recipient does not live in Germany. According to the new regulation, tax is also due on gratuitous transfers to persons who are not subject to unlimited tax liability.

    Additionally, the tax must be paid, among others, by individuals who move their center of vital interests abroad – even if they retain their residence in Germany.

    Similar rules already apply to business investors, such as entrepreneurs, and corporations that hold their investments in business assets, independently of the new Annual Tax Act 2024. For these investors, nothing will change – and they must continue to consider any potential exit taxes.

    The Exit Tax Is 25% of the Increase in Value Since the Acquisition of Shares

    The exit tax amounts to 25% in general of the capital gain since the acquisition. The person leaving must therefore pay the taxes from their own funds if necessary. The taxable capital gain is reduced both by advance lump sums taxed in previous years and by the partial exemption of 30% for equity funds.

    The taxpayer must declare the “exit gain” in their own tax return. No (automatic) final withholding tax is levied.

    Possible Exclusions

    Investors can ensure that the exit tax does not apply or is only payable in installments. Ideally, investors spread their investments across various investment funds at an early stage so the acquisition costs of a single investment are below €500,000 and do not exceed 1% of the investment shares issued. If this is not or no longer possible, investors may consider transferring their investment shares into domestic business assets or transferring them to a foundation. Another possibility is that the investor “retrieves” the investment shares back to the tax authority in Germany within seven years of moving away or transferring them abroad, for example by moving back to Germany and becoming subject to unlimited tax liability.

    If none of these approaches leads to a viable solution, delaying the exit or even the actual sale of the investment shares can be considered. In this case, the tax could at least be paid from the proceeds of sale. In case the tax is not due because of an actual sale, an application can also be filed to defer the tax and to pay it in seven equal annual installments. However, according to the current version of this statute – the legality of which is highly controversial – the application for deferral is usually only granted in return for the provision of security.

    Applicability to Custodian Banks, Investment Funds, and Capital Management Companies

    The new regulation does not affect custodian banks, investment funds, or financial investment management companies. Custodian banks do not have to consider additional withholding taxes.

    Effects on Tax-Optimized Asset Structuring

    The new exit tax puts investments in investment funds at a tax disadvantage compared to direct investments in shares. This is because shares (e.g., in a limited liability company) are only subject to an exit tax if the investor holds at least 1% of the company’s capital – acquisition costs of €500,000 alone are not sufficient. This must be considered in strategic tax planning.

    Reasons for the Change: Equal Treatment With Shareholders

    With the new regulation, the legislator wants to treat holders of investment shares equally with holders of shares in corporations. According to the explanatory memorandum (Bundestag),  a taxpayer could transfer significant corporate shares of at least 1% of the corporation’s equity interest (e.g., shares in a limited liability company) to an investment fund and then acquire all of the investment shares. This taxpayer would not have to pay tax if they moved away – in contrast to the holder of the significant corporate shares. In this context, it is incomprehensible that acquisition costs of at least €500,000 also suffice for the new exit tax, because the amount of the acquisition costs is irrelevant for the previous regulation.

    Authors

    Andreas Klaus, LL.M.

    Associate

    Munich

    Jonathan Storz

    Counsel

    Munich

    More insights